Lupin Q2 Hit By US Settlement, Japan Injectables Selloff

Goa, Somerset Plants Up For Re-inspection Jan-Mar

Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. It's now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary. 

Umberella
One-offs Rained Down On Lupin's Second Quarter • Source: Shutterstock

One-offs can dent earnings sharply - a fact discovered by Lupin Ltd. this quarter. While the Indian firm's sales across all geographies, except Latin America, grew in the second quarter compared to the same term in the previous fiscal year, one-offs from a US lawsuit settlement and sale of its injectables business in Japan tipped the company into an overall loss.

Lupin reported 10% growth in total revenue to INR43.59bn ($610.8m), sheared by exceptional items of INR5.46bn that left the company...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip